Direct‐acting antiviral sustained virologic response: Impact on mortality in patients without advanced liver disease

Lisa I. Backus, Pamela S. Belperio, Troy A. Shahoumian, Larry A. Mole – 29 January 2018 – The impact of sustained virologic response (SVR) on mortality after direct‐acting antiviral (DAA) treatment is not well documented in patients without advanced liver disease and affects access to treatment. This study evaluated the impact of SVR achieved with interferon‐free DAA treatment on all‐cause mortality in hepatitis C virus–infected patients without advanced liver disease.

Reply

Jennifer C. Lai, Kenneth E. Covinsky, Jennifer L. Dodge, W. John Boscardin, Dorry L. Segev, John P. Roberts, Sandy Feng – 29 January 2018

Farnesoid X receptor signaling activates the hepatic X‐box binding protein 1 pathway in vitro and in mice

Xiaoying Liu, Grace L. Guo, Bo Kong, David B. Hilburn, Susan C. Hubchak, Seong Park, Brian LeCuyer, Antony Hsieh, Li Wang, Deyu Fang, Richard M. Green – 29 January 2018 – Bile acids are endogenous ligands of the nuclear receptor, farnesoid X receptor (FXR), and pharmacological FXR modulators are under development for the treatment of several liver disorders. The inositol‐requiring enzyme 1α/X‐box binding protein 1 (IRE1α/XBP1) pathway of the unfolded protein response (UPR) is a protective cellular signaling pathway activated in response to endoplasmic reticulum (ER) stress.

Direct‐acting antiviral sustained virologic response: Impact on mortality in patients without advanced liver disease

Lisa I. Backus, Pamela S. Belperio, Troy A. Shahoumian, Larry A. Mole – 29 January 2018 – The impact of sustained virologic response (SVR) on mortality after direct‐acting antiviral (DAA) treatment is not well documented in patients without advanced liver disease and affects access to treatment. This study evaluated the impact of SVR achieved with interferon‐free DAA treatment on all‐cause mortality in hepatitis C virus–infected patients without advanced liver disease.

Liver atrophy and regeneration in noncirrhotic portal vein thrombosis: Effect of surgical shunts

Abdulrhman S. Elnaggar, Adam D. Griesemer, Stuart Bentley‐Hibbert, Robert S. Brown, Mercedes Martinez, Steven J. Lobritto, Tomoaki Kato, Jean C. Emond – 29 January 2018 – The goal of the study is to characterize the relationship between portal vein thrombosis (PVT) and hepatic atrophy in patients without cirrhosis and the effect of various types of surgical shunts on liver regeneration and splenomegaly. Patients without cirrhosis with PVT suffer from presinusoidal portal hypertension, and often hepatic atrophy is a topic that has received little attention.

Subscribe to